Phase 2 Clinical Trial for Oligorecurrent Prostate Adenocarcinoma Showcases Collaboration Between Jonsson Comprehensive Cancer Center and Novartis Pharmaceuticals

Strategic Insights -

Jonsson Comprehensive Cancer Center has launched a Phase 2 interventional clinical trial, ANDROMEDA, aimed at studying the combination of alpha-emitting or beta-emitting radionuclides with metastasis-directed stereotactic body radiotherapy for oligorecurrent prostate adenocarcinoma. The trial is led by principal investigator Amar Kishan and involves 107 participants from the USA. Although the study is not yet open for recruiting, it promises to explore the efficacy of combining radioactive drugs with radiation therapy for treating recurrent, oligometastatic prostate cancer.

Key Takeaways:

  • The ANDROMEDA trial is designed to compare the use of 225Ac-PSMA-617 and 177Lu-PSMA-617, two radioactive drugs that bind to prostate tumor cells, with metastasis-directed stereotactic body radiotherapy (SBRT) for treating recurrent, oligometastatic prostate cancer.
  • The study involves 107 participants from the USA and aims to investigate the effectiveness of combining radioactive drugs with SBRT in killing tumor cells while sparing normal tissue.
  • The trial will be conducted by the Jonsson Comprehensive Cancer Center in collaboration with Novartis Pharmaceuticals.
  • Stereotactic body radiotherapy (SBRT) is a type of external radiation therapy that uses special equipment to precisely deliver radiation to tumors in the body.
  • The trial will compare the efficacy of 225Ac-PSMA-617 and 177Lu-PSMA-617 in combination with SBRT for treating oligorecurrent prostate adenocarcinoma.
  • The study is listed on ClinicalTrials.gov under the identifier NCT07150715.

Statistics:

  • 107 participants from the USA are expected to participate in the trial.
  • The trial aims to identify the most effective combination of radioactive drugs and radiation therapy for treating recurrent, oligometastatic prostate cancer.
  • The study is a Phase 2 clinical trial, which typically involves a larger number of participants than Phase 1 trials.
  • The trial is not yet open for recruiting, and participants will be selected based on various criteria, including the presence of recurrent, oligometastatic prostate cancer.

Sources:

  • ClinicalTrials.gov: NCT07150715
  • Contify.com: "Jonsson Comprehensive Cancer Center Launches Phase 2 Interventional Clinical Trial for Oligorecurrent Prostate Adenocarcinoma" (no date)